<DOC>
	<DOCNO>NCT01376102</DOCNO>
	<brief_summary>This open label , multi-centre , non-interventional post-marketing surveillance</brief_summary>
	<brief_title>BONVIVA ( Ibandronate ) Injection PMS ( Post-marketing Surveillance )</brief_title>
	<detailed_description>This open label , multi-centre , non-interventional post-marketing surveillance monitor safety Ibandronate injection administer postmenopausal osteoporosis patient accord prescribe information</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : Subjects administer BONVIVA ( ibandronate ) injection follow locally approve prescribe information Women diagnose postmenopausal osteoporosis . Subjects investigator believe comply requirement protocol Subjects experience treatment use ibandronate injection Note : Subjects , experience bisphosphonates treatment , include . Subjects indicate administered ibandronate injection accord Prescribing Information normal prescription use Considering nature noninterventional PMS , strict exclusion criterion set . The doctor participate study enrol subject prescribed ibandronate injection follow locally approve Prescribing Information . The following criterion check time study entry . According contraindication prescribe information , ibandronate injection administer follow patient : Patients know hypersensitivity ibandronate injection excipients Uncorrected hypocalcemia Note : Ibandronate injection recommend use patient serum creatinine 200 Î¼mol/l ( 2.3 mg/dl ) creatinine clearance ( measure estimate ) 30 ml/min , limited clinical data available study include patient .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>ibandronate</keyword>
</DOC>